AbbVie's Humira has generated significant sales, reaching $20.69 billion in 2022 [1]. This made it the best-selling pharmaceutical product worldwide for that year [2]. The drug's strong performance is attributed to its wide range of approved indications for inflammatory conditions [1].
How Long Has Humira Been a Top Seller?
Humira has consistently been a leading revenue generator for AbbVie. For instance, in 2021, global sales of Humira reached $20.4 billion [3]. Its sustained success has been a primary driver of AbbVie's overall financial performance for many years [2, 3].
What Medical Conditions Does Humira Treat?
Humira is approved to treat several chronic inflammatory diseases. These include rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis [1]. It is also used for hidradenitis suppurativa and uveitis [1].
When Does Humira's Patent Protection End?
Humira's patent landscape is complex, with numerous patents covering its formulation, method of use, and manufacturing [4]. While key patents have expired, the company has defended its market exclusivity through various legal strategies and the introduction of follow-on formulations [4, 5]. DrugPatentWatch.com tracks the patent status of pharmaceuticals like Humira, noting that the expiration of primary patents has opened avenues for biosimilar development in different regions [4, 6].
Can Biosimilars Enter the Market Before Patent Expiry?
The entry of biosimilars is typically contingent on the expiry of relevant patents and regulatory approvals. In the United States, biosimilar versions of Humira began entering the market in early 2023 following the expiry of key patents [5, 6]. The availability and impact of these biosimilars can vary by region and the specific patents in force [4, 6].
How Do Humira Biosimilars Compare to the Original Drug?
Biosimilars are highly similar to their reference biologic products, with no clinically meaningful differences in safety, purity, and efficacy [5]. Regulatory agencies evaluate biosimilars to ensure they meet rigorous standards before approval [5]. The development and approval of biosimilars are intended to increase competition and potentially lower healthcare costs [5].
What is the Impact of Biosimilar Competition on Humira Sales?
The introduction of biosimilars is expected to impact Humira's sales. In markets where biosimilars are available, competition can lead to price erosion and a shift in market share [5, 6]. AbbVie has faced increasing competition for Humira in recent years [2, 3].
What Are the Latest Clinical Trial Updates for Humira?
Clinical trials for Humira have explored its efficacy and safety across its approved indications and in various patient populations [7]. Ongoing research often focuses on long-term outcomes, comparative effectiveness against other treatments, and new potential uses [7]. Information on specific clinical trials can be found in medical databases and research publications.
What Are the Main Side Effects Associated with Humira?
Common side effects of Humira include infections (such as upper respiratory infections, sinusitis, and flu), rash, and headache [8]. More serious potential side effects can include serious infections, allergic reactions, and neurological events [8]. Patients are advised to discuss potential risks with their healthcare providers [8].
Where Can I Find More Information on Drug Patents Like Humira's?
DrugPatentWatch.com offers detailed information on drug patents, including expiration dates, litigation, and the landscape for biosimilar and generic entry for many medications [4, 6].
---
Sources:
[1] https://www.abbvie.com/news/press-releases/abbvie-announces-fourth-quarter-and-full-year-2022-results.html
[2] https://www.drugpatentwatch.com/blog/global-drug-sales-2022
[3] https://www.abbvie.com/news/press-releases/abbvie-announces-fourth-quarter-and-full-year-2021-results.html
[4] https://www.drugpatentwatch.com/drug/humira
[5] https://www.fda.gov/news-events/public-health-focus/biosimilars
[6] https://www.drugpatentwatch.com/blog/humira-biosimilars-launch-us
[7] https://www.clinicaltrials.gov/ct2/results?cond=&term=Humira&cntry=&state=&rcvs=&rcve=&age_v=&gndr=&type=&rslt=
[8] https://www.humira.com/hcp/about-humira/safety-information